Wednesday
October 13
2021

Analysis: Moderna, Racing for Profits, Keeps COVID Vaccine Out of Reach of Poor

By Rebecca Robbins

Moderna, whose coronavirus vaccine appears to be the world’s best defense against Covid-19, has been supplying its shots almost exclusively to wealthy nations, keeping poorer countries waiting and earning billions in profit.

After developing a breakthrough vaccine with the financial and scientific support of the U.S. government, Moderna has shipped a greater share of its doses to wealthy countries than any other vaccine manufacturer, according to Airfinity, a data firm that tracks vaccine shipments.

About one million doses of Moderna’s vaccine have gone to countries that the World Bank classifies as low income. By contrast, 8.4 million Pfizer doses and about 25 million single-shot Johnson & Johnson doses have gone to those countries.

Photo courtesy of Mufid Majnun.

Source: The New York Times (link opens in a new window)

Categories
Coronavirus, Health Care
Tags
coronavirus, emerging markets, healthcare, LMICs, pandemics, sustainability, vaccines